Sanofi

Sanofi said the French healthcare group priced a first sustainability-linked bond issue that will be indexed on access to medicines, and worth 1.5 billion euros ($1.7 billion).

Sanofi

Paris-based Sanofi and Mountain View, California-based IGM Biosciences inked a collaboration deal for oncology, immunology and inflammation that could surpass $6 billion.

Sanofi’s shares slid 5 percent on March 14 after a product candidate to fight a common type of breast cancer failed to slow progression of the disease in a clinical trial, knocking confidence in the French drugmaker’s drug development prowess.

BioNTech announced an expansion of a collaboration with Regeneron Pharmaceuticals to continue advancing mRNA technology and develop the FixVac candidate BNT116 in combination with Regeneron and Sanofi’s shared pharmaceutical product Libtayo (cemiplimab) for non-small cell lung cancer.

Sanofi

Sanofi and partner Swedish Orphan Biovitrum shared positive topline results from their ongoing Phase III trial on a candidate drug for patients diagnosed with severe hemophilia A. 

The latest results from Sanofi and AstraZeneca’s Phase III trial for nirsevimab demonstrate the vaccine’s ability to protect all infants from the respiratory syncytial virus (RSV) with a single dose.

Sanofi

Shares of Adagene Incorporated were up in trading on March 2 after the company announced a monoclonal and bispecific antibody collaboration with Sanofi that is valued at up to $2.5 billion.

Sanofi

French drugmaker Sanofi and the company’s British partner GlaxoSmithKline are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot, after several setbacks.

Regeneron and Sanofi announced that a late-stage trial for the blockbuster anti-inflammatory drug Dupixent for patients with chronic spontaneous urticaria (CSU) was halted due to futility.

The U.S. Food and Drug Administration approved Sanofi’s proposed drug to address red blood cell destruction in patients living with a rare form of anemia called cold agglutinin disease (CAD).